Q2
CRMD — Q2 2026 Financial Report Analysis
CorMedix's Q2 2026 revenue rose 156.5% to $101.9M on DefenCath and the Melinta acquisition, with $26.0M net income, but guidance implies second-half revenue roughly halves after DefenCath's Medicare add-on payment ended July 1.